Han et al. (2019) reported Ythdf1-deficient mice exhibit an enhanced antigen-specific CD8+ T cell anticancer response. Also, the loss of YTHDF1 can improve the therapeutic effectiveness of PD-L1 checkpoint blockade, thus indicating YTHDF1 might be a promising therapeutic target in immunotherapy. Notably, ZC3H13 expression is reported to be positively associated with infiltrating immune cells, thereby facilitating the elimination of HCC cells and eventually improving prognosis (Xu et al., 2021). Here, YTHDF1 is linked to hepatocellular carcinoma.